Cantargia AB (CHIX:CANTAS) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 27, 2026)


CHIX:CANTAS Cantargia AB CHIX:CANTAS
37 GF Score
Price kr4.17
! 2 Warning Signs
View Full Analysis

What is Cantargia AB Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Cantargia AB's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

CHIX:CANTAS vs VRTX, REGN, ALNY: Margin of Safety % (DCF Earnings Based) Comparison

For the Biotechnology subindustry, Cantargia AB's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cantargia AB Margin of Safety % (DCF Earnings Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cantargia AB's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Cantargia AB's Margin of Safety % (DCF Earnings Based) falls into.


CHIX:CANTAS
37GF Score
Cantargia AB CHIX:CANTAS
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cantargia AB Business Description

Other Exchanges CANTA:Sweden7V3:Germany
Address Scheelevagen 27, Lund, SWE, 223 63
Cantargia AB is a Swedish biotech company that develops targeted antibody-based drugs for cancer as well as autoimmune and inflammatory diseases. It has developed specific antibodies against IL1RAP to treat serious, life-threatening diseases. The company's development programme includes the candidate drugs nadunolimab (CAN04) and CAN10, both in the clinical development stage, which were latter acquired by Otsuka Pharmaceutical in 2025. In addition, the company is also developing a a pre-clinical project CAN14, derived from antibody platform CANxx. Geographically, the company's revenues have been generated in the markets of Japan and United States.
37GF Score

Get the complete analysis for CHIX:CANTAS

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr4.17
Price